GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoSec Medical Inc (OTCPK:ONCSQ) » Definitions » Asset Turnover

OncoSec Medical (OncoSec Medical) Asset Turnover : 0.00 (As of Jan. 2023)


View and export this data going back to 1986. Start your Free Trial

What is OncoSec Medical Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. OncoSec Medical's Revenue for the three months ended in Jan. 2023 was $0.00 Mil. OncoSec Medical's Total Assets for the quarter that ended in Jan. 2023 was $11.66 Mil. Therefore, OncoSec Medical's Asset Turnover for the quarter that ended in Jan. 2023 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. OncoSec Medical's annualized ROE % for the quarter that ended in Jan. 2023 was 848.35%. It is also linked to ROA % through Du Pont Formula. OncoSec Medical's annualized ROA % for the quarter that ended in Jan. 2023 was -235.47%.


OncoSec Medical Asset Turnover Historical Data

The historical data trend for OncoSec Medical's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSec Medical Asset Turnover Chart

OncoSec Medical Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

OncoSec Medical Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of OncoSec Medical's Asset Turnover

For the Biotechnology subindustry, OncoSec Medical's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoSec Medical's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoSec Medical's Asset Turnover distribution charts can be found below:

* The bar in red indicates where OncoSec Medical's Asset Turnover falls into.



OncoSec Medical Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

OncoSec Medical's Asset Turnover for the fiscal year that ended in Jul. 2022 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Jul. 2022 )/( (Total Assets (A: Jul. 2021 )+Total Assets (A: Jul. 2022 ))/ count )
=0/( (56.276+21.878)/ 2 )
=0/39.077
=0.00

OncoSec Medical's Asset Turnover for the quarter that ended in Jan. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jan. 2023 )/( (Total Assets (Q: Oct. 2022 )+Total Assets (Q: Jan. 2023 ))/ count )
=0/( (14.439+8.871)/ 2 )
=0/11.655
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


OncoSec Medical  (OTCPK:ONCSQ) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

OncoSec Medical's annulized ROE % for the quarter that ended in Jan. 2023 is

ROE %**(Q: Jan. 2023 )
=Net Income/Total Stockholders Equity
=-27.444/-3.235
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-27.444 / 0)*(0 / 11.655)*(11.655/ -3.235)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*-3.6028
=ROA %*Equity Multiplier
=-235.47 %*-3.6028
=848.35 %

Note: The Net Income data used here is four times the quarterly (Jan. 2023) net income data. The Revenue data used here is four times the quarterly (Jan. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

OncoSec Medical's annulized ROA % for the quarter that ended in Jan. 2023 is

ROA %(Q: Jan. 2023 )
=Net Income/Total Assets
=-27.444/11.655
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-27.444 / 0)*(0 / 11.655)
=Net Margin %*Asset Turnover
= %*0
=-235.47 %

Note: The Net Income data used here is four times the quarterly (Jan. 2023) net income data. The Revenue data used here is four times the quarterly (Jan. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


OncoSec Medical Asset Turnover Related Terms

Thank you for viewing the detailed overview of OncoSec Medical's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoSec Medical (OncoSec Medical) Business Description

Traded in Other Exchanges
N/A
Address
24 North Main Street, Pennington, NJ, USA, 08534
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.
Executives
Robert J Delaversano officer: Principal Accounting Officer 217 W. MAIN STREET, SOMERVILLE NJ 08876
Spahr Stephany Foster director C/O ONCOSEC MEDICAL, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Robert H. Arch officer: President and CEO C/O ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
George Chi officer: Chief Financial Officer 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Lin Shi director 24 NORTH MAIN STREET, PENNINGTON NJ 08534-2218
Margaret Dalesandro director ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Yuhang Zhao director 6 HORTON DR., CHESTER NJ 07930
Brian A Leuthner officer: Chief Operating Officer 200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Daniel J. O'connor director C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
China Grand Pharmaceutical & Healthcare Holdings Ltd 10 percent owner, other: See Remarks UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000
Alpha Holdings, Inc. director, 10 percent owner GANGNAM-GU APGUJEONG-RO 62-GIL 17-10, SEOUL M5 06016
Kellie Malloy Foerter officer: Chief Operating Officer C/O ONCOSEC MEDICAL INCORPORATED, 24 N. MAIN STREET, PENNINGTON NJ 08534-2218
Herbert Kim Lyerly director C/O ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534-2218
Chao Zhou director UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000
Grand Decade Developments Ltd 10 percent owner, other: See Remarks UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000

OncoSec Medical (OncoSec Medical) Headlines

From GuruFocus